News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Quarterly Shareholder Update and Investor Briefing
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 29 April 2022.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Friday 29 April 2022.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
https://www.pharmaxis.com.au/investor-centre/investor-briefing/
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au
Read full media release - pdfPharmaxis R&D Showcase Webinars - Recordings
Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods.
Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers.
|
Presentation |
Speaker |
Link to recording |
|
Welcome and Introduction to Pharmaxis research and clinical development program |
Michael Woods Dr Wolfgang Jarolimek Gary Phillips |
|
|
The myelofibrosis landscape and MF-101 |
Dr Gabriela Hobbs (Massachusetts General Hospital) |
|
|
Hepatocellular cancer and Rochester University investigator led study |
Dr Paul Burchard (Rochester NY) |
|
|
Pancreatic Cancer |
Dr Tom Cox |
|
|
Pharmaxis Q&A |
Gary Phillips |
Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)
A pdf of the presentations is available here.
Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.
|
Presentation |
Speaker |
Link to recording |
|
Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology |
Gary Phillips |
|
|
The science of scarring and potential for LOX inhibition |
Dr Mark Fear (UWA) |
|
|
Clinical applications for LOX inhibition |
Professor Fiona Wood (UWA) |
|
|
Q&A with panel |
Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)
A pdf of the presentations is available here.